Overview

• Bristol Myers Squibb's Q2 revenue reached $12.2 billion, surpassing analyst estimates of $11.55 billion.
• Adjusted earnings per share for Q2 were $2.07, significantly higher than the expected $1.63.
• Sales of key drugs like Eliquis and Opdivo contributed to the company's robust performance.
• The company raised its full-year revenue and earnings guidance, projecting continued growth.
• Cost-cutting measures are expected to save $1.5 billion by 2025, further boosting profitability.